Regulatory Framework
The QIP was conducted under Chapter VI of the SEBI ICDR Regulations, 2018, and Sections 42 and 62 of the Companies Act, 2013.
Approval History
The Board of Directors approved the QIP at its meeting on July 24, 2026. Shareholders approved the offering through a special resolution passed on August 21, 2026.
Committee Meeting Details
The Fund-Raising Committee meeting commenced at 9:30 p.m. and concluded at 9:51 p.m. on September 16, 2026.
Key Committee Resolutions
- Approved closure of the QIP issue period on September 16, 2026, following receipt of applications for 26,60,753 fully paid-up equity shares and corresponding funds in escrow
- Determined and approved the issue price of ₹2,255 per equity share (face value ₹10, premium ₹2,245) in consultation with lead managers
- Approved and adopted the placement document dated September 16, 2026
- Approved finalization of allocation notes to be sent to eligible qualified institutional buyers
QIP Details
- Total shares allotted: 26,60,753 equity shares of face value ₹10 each
- Issue price: ₹2,255 per share (including premium of ₹2,245)
- Issue opening date: September 10, 2026
- Allottees: Eligible qualified institutional buyers
Financial Impact
The QIP raised approximately ₹600.00 crore (26,60,753 shares × ₹2,255 per share).
Filing Requirements
The company will file the placement document dated September 16, 2026, with BSE Limited (Scrip Code: 542665, Debt Segment Code: 977028) and National Stock Exchange of India Limited (Company Symbol: NEOGEN).
Public Disclosure
The placement document and this intimation are available on the company's website at https://neogenchem.com/announcements/ under the 'Issue of Securities' tab.